AI in Biotech Finance

AI in biotech deal structuring: how to model partnerships before you sign them In 2025, AI and machine learning drug discovery licensing deals totalled $43.4 billion across 114 transactions. That is a significant acceleration from prior years, and the deals are getting more structurally complex. Platform licensing deals, foundation model partnerships, and multi-asset collaboration agreements […]

Neurocrine acquires Soleno for $2.9B: what the deal signals about the 2026 M&A wave Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion in cash. The deal is Neurocrine’s largest acquisition ever and adds Vykat XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, to its rare disease